-
Combination flu-COVID drug study paused after 'serious adverse event'
The FDA has placed a clinical hold on Novavax's application for its COVID-19-Influenza combination and standalone influenza vaccine candidates following a report of a "serious adverse event." -
Why hundreds of US pharmacies are closing
Changing consumer trends and market dynamics are leading to hundreds of pharmacy store closures in the U.S. -
Texas system creates 3D-printed meds for infection
College Station-based Texas A&M University researchers are developing a way to 3D-print pediatric medications for toxoplasmosis, an infection caused by parasites. -
UCSF Health opens 2 outpatient facilities
San Francisco-based UCSF Health opened new retail pharmacies at its Mission Bay and Parnassus, Calif., campuses, offering comprehensive and accessible health services. -
90% of independent pharmacies may not stock drugs in negotiation program: Study
A new survey by the National Community Pharmacists Association found that more than 90% of independent pharmacists may refuse to sell drugs targeted by Medicare Part D negotiations, potentially jeopardizing the Biden administration's efforts to lower prescription costs. -
Smaller vial for Alzheimer's drug could save Medicare $366M per year: Study
A new study suggests that Medicare could save up to $366 million annually by introducing a new vial size for Alzheimer's drug lecanemab, which is currently only available in single-use, 500- and 200-milligram vials. -
Another DSCSA enforcement delay: 4 things to know
The FDA has granted another exemption from certain requirements of the Drug Supply Chain Security Act to help eligible trading partners address challenges with data exchange while ensuring patient access to medications. -
New drug can treat common nasal disease: GSK
GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population. -
Sanofi in talks to sell 50% stake in consumer health business
Sanofi is entering negotiations with Clayton, Dublier & Rice regarding the potential sale of a 50% controlling stake in its consumer health business, Opella. -
Massachusetts pharmacist sentenced to 15 years for meningitis outbreak
Massachusetts pharmacist Glenn Chin was sentenced Oct. 11 in Michigan to 7 1/2 to 15 years in prison for his involvement in a 2012 meningitis outbreak that led to 11 deaths in Michigan and dozens more across the country, The Washington Post reported Oct. 11. -
FDA to reconsider decision barring sale of compounded Mounjaro: 5 things to know
The FDA has decided to reconsider its recent ban on the sale of compounded versions of tirzepatide, according to court documents obtained by Becker's. -
Pharmacy deserts appearing across US amid Rite Aid, Walgreens and CVS closures
The landscape of community healthcare in the U.S. has been changing rapidly as major drugstore chains like Rite Aid, Walgreens and CVS announced widespread closures leading to widespread "pharmacy deserts," CNBC reported Oct. 11. -
What to know about biosimilars?
The Biologics Price Competition and Innovation Act of (BPCI Act) of 2009 granted responsibility to the FDA for review and approval of a new class of pharmaceuticals referred to as "Biosimilars." (1) -
Abortion pill maker to seek its use to miscarriage: Wall Street Journal
Danco Laboratories is planning to seek FDA approval for the use of abortion pill Mifeprex for the treatment of miscarriages, The Wall Street Journal reported Oct. 8. -
GSK agrees to settle 80,000 Zantac lawsuits for $2.2B
GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion. -
FDA approves 1st combination COVID-flu test: 4 things to know
The FDA authorized the Healgen Rapid Check COVID-19/Flu A&B Antigen Test for over-the-counter use, the first combination test to receive approval outside of an emergency context, ABC News reported Oct. 8. -
2 Alzheimer's drugs show promise in slowing cognitive decline
The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8. -
CMS proposes $2 Medicare drug list: 5 things to know
CMS published a list of generic drugs to be included under its proposed Medicare $2 Drug List Model Oct. 9. -
Pharmacists urge federal action over IV shortage
The American Society of Health-System Pharmacists is urging federal health officials to declare a national public health emergency over the IV fluid shortage. -
Healthcare organizations file brief defending Minnesota 340B law: 4 notes
A coalition of healthcare organizations led by the American Hospital Association has filed an amicus brief defending Minnesota's law protecting the 340B drug discount program.
Page 5 of 50